Table 2.
Child–Pugh scores at Week 8
| Patients with Child–Pugh B at Week 8, n | Patients with available BCDM-determined Child–Pugh score points, n a |
Child–Pugh score (Week 8) n (%) b |
|||
|---|---|---|---|---|---|
| 7 points | 8 points | 9 points | |||
| Cabozantinib | 51 | 42 | 26 (51) | 11 (22) | 3 (6) |
| Placebo | 22 | 21 | 11 (50) | 3 (14) | 5 (23) |
aTwo patients each in the cabozantinib and placebo cohorts had a score of 6. As Child–Pugh grading was investigator assessed and Child–Pugh scoring was determined independently by BCDM, some discrepancies between grading and scoring results existed. bPercentage of total number of patients who developed Child–Pugh B cirrhosis. BCDM Biostatistics and Clinical Data Management